![]() The production of safe, efficacious and affordable monoclonal antibodies in surplus quantities warrants advanced process strategies to overcome the disadvantages of conventional methods. The requirement of monoclonal antibodies (mAbs) as therapeutic agents and also in diagnostic applications is rising continually after the successful Nobel Prize-winning discovery of hybridoma technology by Georges Kohler and Cesar Milstein in 1975. These developments in high-density cell culture systems have led to the monoclonal antibody production in an economically favourable manner and made monoclonal antibodies one of the dominant therapeutic and diagnostic proteins in biopharmaceutical industry. Packed bed systems and disposable wave bioreactors have also been introduced for high cell density culture. As an alternative to hollow fiber reactors, a novel disposable bioreactor has been developed, which consists of a polymer-based supermacroporous material, cryogel, as a matrix for cell growth. Among the reactors, hollow fiber bioreactors contribute to a major part of high-density cell culture as they can provide a tremendous amount of surface area in a small volume for cell growth. This review describes recent trends in high-density cell culture systems established for monoclonal antibody production that are excellent methods to scale up from the lab-scale cell culture. To produce these proteins in sufficient quantities for commercial use, it is necessary to raise the output by scaling up the production processes. Monoclonal antibodies are widely used as diagnostic reagents and for therapeutic purposes, and their demand is increasing extensively. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |